• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up2.00% Nasdaq Up1.66%

    Keryx Biopharmaceuticals Inc. (KERX)

    -NasdaqCM
    3.43 Up 0.19(5.71%) Feb 12, 3:59PM EST
    ProfileGet Profile for:
    Keryx Biopharmaceuticals Inc.
    750 Lexington Avenue
    20th Floor
    New York, NY 10022
    United States - Map
    Phone: 212-531-5965
    Fax: 212-531-5961
    Website: http://www.keryx.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:154

    Business Summary 

    Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on providing therapies for patients with renal disease in the United States. Its lead product Auryxia (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate in the gastrointestinal tract and form non-absorbable complexes, as well as treats iron deficiency anemia. Auryxia is also used to control serum phosphorus levels in patients with chronic kidney disease on dialysis. The company also has sublicense agreements with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of Auryxia in Japan. It also has strategic alliance with Panion & BF Biotech, Inc. Keryx Biopharmaceuticals, Inc. was founded in 1997 and is headquartered in New York, New York.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Keryx Biopharmaceuticals Inc.

    Corporate Governance 
    Keryx Biopharmaceuticals Inc.’s ISS Governance QuickScore as of Feb 1, 2016 is 6. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 5; Compensation: 7.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Mr. Gregory P. Madison , 48
    Chief Exec. Officer, Pres, Director and Member of R&D Committee
    537.00K0.00
    Mr. Scott A. Holmes M.S., M.B.A., CPA, 42
    Chief Financial Officer
    N/AN/A
    Dr. Enrique Poradosu Ph.D.,
    VP of Scientific & Bus. Strategy
    N/AN/A
    Lora Pike ,
    Sr. Director of Investor Relations
    N/AN/A
    Mr. Brian R. Adams , 42
    Gen. Counsel and Sec.
    N/AN/A
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders